GAVASSO, SABRINA
 Distribuzione geografica
Salva come PNG Salva come JPEG
Continente #
NA - Nord America 6.090
AS - Asia 1.674
EU - Europa 1.282
AF - Africa 466
SA - Sud America 420
OC - Oceania 56
Continente sconosciuto - Info sul continente non disponibili 29
Totale 10.017
Salva come PNG Salva come JPEG
Nazione #
US - Stati Uniti d'America 5.831
SG - Singapore 535
CN - Cina 360
BR - Brasile 272
HK - Hong Kong 223
IT - Italia 223
FI - Finlandia 133
DE - Germania 127
SE - Svezia 89
VN - Vietnam 76
NL - Olanda 64
PL - Polonia 60
FR - Francia 59
GB - Regno Unito 55
RU - Federazione Russa 51
IN - India 42
UA - Ucraina 41
AT - Austria 33
TR - Turchia 28
IE - Irlanda 25
MX - Messico 25
ZA - Sudafrica 25
CA - Canada 22
AZ - Azerbaigian 21
DO - Repubblica Dominicana 21
ES - Italia 21
PY - Paraguay 21
PE - Perù 20
CO - Colombia 18
ML - Mali 18
BG - Bulgaria 17
EC - Ecuador 17
SA - Arabia Saudita 17
CI - Costa d'Avorio 16
CY - Cipro 16
CZ - Repubblica Ceca 16
EE - Estonia 16
KE - Kenya 16
KG - Kirghizistan 16
LB - Libano 16
LV - Lettonia 16
MY - Malesia 16
PA - Panama 16
CL - Cile 15
LY - Libia 15
ME - Montenegro 15
NI - Nicaragua 15
PH - Filippine 15
RO - Romania 15
SD - Sudan 15
SN - Senegal 15
TW - Taiwan 15
AE - Emirati Arabi Uniti 14
BE - Belgio 14
CG - Congo 14
CH - Svizzera 14
GA - Gabon 14
GH - Ghana 14
GR - Grecia 14
ID - Indonesia 14
IL - Israele 14
IQ - Iraq 14
KH - Cambogia 14
LA - Repubblica Popolare Democratica del Laos 14
MN - Mongolia 14
MU - Mauritius 14
NP - Nepal 14
PK - Pakistan 14
UY - Uruguay 14
AO - Angola 13
AU - Australia 13
CW - ???statistics.table.value.countryCode.CW??? 13
HN - Honduras 13
JM - Giamaica 13
JP - Giappone 13
KR - Corea 13
SK - Slovacchia (Repubblica Slovacca) 13
TJ - Tagikistan 13
BJ - Benin 12
CU - Cuba 12
CV - Capo Verde 12
ET - Etiopia 12
GE - Georgia 12
GF - Guiana Francese 12
GM - Gambi 12
IS - Islanda 12
MD - Moldavia 12
MW - Malawi 12
NZ - Nuova Zelanda 12
PS - Palestinian Territory 12
RS - Serbia 12
UZ - Uzbekistan 12
ZM - Zambia 12
AR - Argentina 11
BA - Bosnia-Erzegovina 11
BB - Barbados 11
CD - Congo 11
EG - Egitto 11
HR - Croazia 11
HT - Haiti 11
Totale 9.497
Salva come PNG Salva come JPEG
Città #
Fairfield 924
Woodbridge 550
Chandler 501
Ashburn 481
Ann Arbor 375
Houston 364
Seattle 358
Singapore 341
Cambridge 320
Wilmington 277
Hong Kong 214
Beijing 132
Boardman 114
Santa Clara 109
Jacksonville 105
San Diego 94
Princeton 83
Des Moines 63
Helsinki 63
Los Angeles 56
Medford 54
Padova 51
Chicago 50
Munich 40
Roxbury 39
Bytom 36
Villafranca Padovana 32
Dong Ket 31
Nanjing 29
Buffalo 27
New York 23
Vienna 21
Baku 20
Shenyang 20
Dublin 19
London 18
Bamako 17
Brooklyn 17
Hefei 17
Ho Chi Minh City 17
Milan 17
Salt Lake City 17
Rio de Janeiro 16
São Paulo 16
Abidjan 15
Dakar 15
Falls Church 15
Hebei 15
Nairobi 15
Panama City 14
Ulan Bator 14
Atlanta 13
Bishkek 13
Dushanbe 13
Libreville 13
Managua 13
Riga 13
Dallas 12
Havana 12
Luanda 12
Montevideo 12
Montreal 12
Nuremberg 12
Phnom Penh 12
Tashkent 12
Accra 11
Amman 11
Antananarivo 11
Bridgetown 11
Cotonou 11
Lusaka 11
Podgorica 11
Sofia 11
Vientiane 11
Willemstad 11
Banjul 10
Castries 10
Johannesburg 10
Kampala 10
Khartoum 10
Nanchang 10
Nassau 10
Nicosia 10
Nouakchott 10
Noumea 10
Padua 10
Quito 10
Reykjavik 10
Stockholm 10
Tripoli 10
Turku 10
Addis Ababa 9
Amsterdam 9
Guangzhou 9
Kinshasa 9
Lappeenranta 9
Ouagadougou 9
Papeete 9
Pristina 9
Tallinn 9
Totale 6.796
Salva come PNG Salva come JPEG
Nome #
X-linked thrombophilia with a mutant factor IX (factor IX Padua). 205
Dynamics of circulating microparticles in obesity after weight loss 196
Non-invasive risk stratification after HCV-eradication in patients with advanced chronic liver disease 178
In vitro and in vivo effects of the carbon monoxide-releasing molecule, CORM-3, in the xenogeneic pig-to-primate context 175
Endothelial damage of the portal vein is associated with Heparin-like effect in advanced stages of cirrhosis 174
Association between ABO blood group and bleeding phenotype in patients with mild rare bleeding disorders 171
The incidence of venous thromboembolism in carriers of antithrombin, protein C or protein S deficiency associated with the HR2 haplotype of factor V: a family cohort study 170
Does decreased fibrinolysis have a role to play in the development of non-neoplastic portal vein thrombosis in patients with hepatic cirrhosis? 169
Circulating microparticles and the risk of thrombosis in inherited deficiencies of antithrombin, protein C and protein S 167
Alterations in the coagulation profile in renal pig-to-monkey xenotransplantation 165
Platelet factor V levels in moderate to severe congenital factor V deficiency. 159
Perioperative coagulation assessment of patients undergoing major elective orthopedic surgery 159
Hypercoagulability detected by circulating microparticles in patients with hepatocellular carcinoma and cirrhosis 158
Hypercoagulability in overweight and obese subjects who are asymptomatic for thrombotic events 156
Factor IX activity/antigen ratio and the risk of first unprovoked venous thromboembolism. 155
Factor VIIa-antithrombin complexes in patients with non-neoplastic portal vein thrombosis with and without cirrhosis. 153
Effects of long-term administration of recombinant human protein C in xenografted primates. 153
The clinical performance of a chemiluminescent immunoassay in detecting anti-cardiolipin and anti-β2 glycoprotein i antibodies. A comparison with a homemade ELISA method 150
Increased anticoagulant response to low-molecular-weight heparin in plasma from patients with advanced cirrhosis 148
Peculiar laboratory phenotype/ genotype relationship due to compound inherited protein C defects in a child with severe venous thromboembolism 147
Endothelial, platelet, and tissue factor-bearing microparticles in cancer patients with and without venous thromboembolism. 147
Residual platelet factor V ensures thrombin generation in patients with severe congenital factor V deficiency and mild bleeding symptoms 145
Acute Kidney Injury in Decompensated Cirrhosis Is Associated With Both Hypo-coagulable and Hyper-coagulable Features 145
"Pseudo homozygous" activated protein C resistance due to double heterozygous factor V defects (factor V Leiden mutation and type I quantitative factor V defect) associated with thrombosis: report of two cases belonging to two unrelated kindreds. 144
Thrombin generation in Cushing's Syndrome: do the conventional clotting indices tell the whole truth? 143
Thrombin generation in patients with COVID-19 with and without thromboprophylaxis 143
“In vitro” correction of the severe factor V deficiency-related coagulopathy by a novel plasma-derived factor V concentrate 142
Direct Oral Anticoagulants in Patients With Inherited Thrombophilia and Venous Thromboembolism: A Prospective Cohort Study 138
Factor VIIa-antithrombin complexes in children with ischemic stroke. 137
Reversal of hypercoagulability in patients with HCV-related cirrhosis after treatment with direct acting antivirals 137
Origin and levels of circulating microparticles in normal pregnancy: A longitudinal observation in healthy women 136
Low plasma levels of tissue factor pathway inhibitor in patients with congenital factor V deficiency. 134
Evaluation of a procoagulant phospholipid functional assay as a routine test for measuring circulating microparticle activity. 132
Factor VIIa-antithrombin complexes in patients with arterial and venous thrombosis. 131
Thromboelastographic evaluation of coagulative profiles in pig-to-monkey kidney xenotransplantation. 130
Partial F8 gene duplication (Factor VIII Padua) associated with high factor VIII levels and familial thrombophilia 130
Profiling plasma alterations of extracellular vesicles in patients with acutely decompensated cirrhosis and bacterial infection 127
Genetic modulation of the FV(Leiden)/normal FV ratio and risk of venous thrombosis in factor V Leiden heterozygotes. 127
Identification of a novel frameshift mutation causing a premature stop codon in a young Nigerian man with type I antithrombin deficiency. 127
Reference values for thromboelastometry (ROTEM®) in cynomolgus monkeys (Macaca fascicularis). 127
The haemostatic system in acromegaly: a single-centre case–control study 127
Soluble endothelial protein C receptor (sEPCR) levels and venous thromboembolism in carriers of two dysfunctional protein C variants 124
Thrombin activatable fibrinolysis inhibitor in cancer patients with and without venous thromboembolism. 124
Local prothrombotic state in portal venous system in cirrhosis 124
null 122
Coagulopathy is not predictive of bleeding in patients with acute decompensation of cirrhosis and acute-on-chronic liver failure 122
A protein S functional assay yields unsatisfactory results in patients with activated protein C resistance. 121
Prothrombin antigen levels in symptomatic and asymptomatic carriers of the 20210A prothrombin variant. 121
Effect on thrombin generation of the "in vitro" addition of low-dose LMWH to plasma of healthy pregnant and nonpregnant women. 121
Endocytosis of exogenous factor V by ex-vivo differentiated megakaryocytes from patients with severe parahaemophilia 121
The risk of arterial thrombosis in carriers of natural coagulation inhibitors: a prospective family cohort study 121
The role of antiphospholipid antibodies toward the protein C/protein S system in venous thromboembolic disease. 120
Similar hypercoagulable state and thrombosis risk in type Iand type III protein S-deficient individuals from families with mixed type I/IIIprotein S deficiency. 117
Circulating microparticles in carriers of prothrombin G20210A mutation. 117
Circulating microparticles in carriers of factor V Leiden with and without a history of venous thrombosis. 115
Determinants of increased thrombotic tendency in NASH cirrhosis: not there yet! 114
Increased platelet aggregation in patients with decompensated cirrhosis indicates higher risk of further decompensation and death 112
Prothrombin fragment 1+2 and thrombin-antithrombin complex levels in patients with inherited APC resistance due to factor V Leiden mutation. 111
Factor VIIa-antithrombin complexes plasma levels in cancer patients with and without thrombosis. 111
Coagulation factor XI in cirrhosis does not predict thrombo-hemorrhagic complications and hepatic decompensation 110
Differential effects of high prothrombin levels on thrombin generation depending on the cause of the hyperprothrombinemia. 109
Soluble endothelial protein C receptor (sEPCR) levels and venous thromboembolism in carriers of two dysfunctional protein C variants. 106
Longitudinal Trend of Plasma Concentrations of Extracellular Vesicles in Patients Hospitalized for COVID-19 104
Global hemostatic profiling in patients with decompensated cirrhosis and bacterial infections 102
Reply to "Peripheral versus central venous blood sampling does not influence the assessment of platelet activation in cirrhosis" 100
Assessing Clinically Meaningful Hypercoagulability after COVID-19 Vaccination: A Longitudinal Study 98
Absence of hypercoagulability after nCoV-19 vaccination: An observational pilot study 97
Thrombosis and thrombophilia in children: a systematic review. 95
Contact system and intrinsic pathway activation in patients with advanced pancreatic cancer: a prospective cohort study 93
Reticulated platelets are increased and hyper-activated in patients with cirrhosis, especially those with poor outcome 92
Severity of systemic inflammation is the main predictor of ACLF and bleeding in patients with acutely decompensated cirrhosis 89
Influence of hepatocellular carcinoma on platelet aggregation in cirrhosis 88
Role of local endothelial alterations in the pathogenesis of portal vein thrombosis in cirrhosis 87
Impaired whole blood thrombin generation is associated with procedure-related bleeding in acutely decompensated cirrhosis 86
More Pronounced Hypercoagulable State and Hypofibrinolysis in Patients With Cirrhosis With Versus Without HCC 86
Long term use of oral contraceptives without thrombosis in patients with FV Leiden polymorphism: a study of 37 patients (2 homozygous and 35 heterozygous). 85
Whole blood thrombin generation shows a significant hypo-coagulable state in patients with decompensated cirrhosis 78
Activation of the Contact System and Intrinsic Pathway in Peripheral and Portal Venous Circulations in Liver Cirrhosis 56
Detection of IgG anti-Domain I beta2 Glycoprotein I antibodies by chemiluminescence immunoassay in primary antiphospholipid syndrome. 44
Recompensation after acute decompensation in alcohol-related cirrhosis is rare and likely unrelated to platelet-poor plasma thrombin generation and fibrinolysis 8
Totale 10.108
Salva come PNG Salva come JPEG
Categoria #
all - tutte 34.420
article - articoli 33.611
book - libri 0
conference - conferenze 0
curatela - curatele 0
other - altro 0
patent - brevetti 0
selected - selezionate 0
volume - volumi 0
Totale 68.031
Salva come PNG Salva come JPEG


Totale Lug Ago Sett Ott Nov Dic Gen Feb Mar Apr Mag Giu
2020/2021819 0 0 0 123 94 56 39 91 110 103 105 98
2021/20221.122 56 108 159 36 53 106 57 98 62 44 109 234
2022/2023857 168 114 49 96 139 103 5 50 85 4 39 5
2023/2024379 16 70 45 48 22 45 19 10 13 20 29 42
2024/20251.887 3 124 100 64 236 60 120 149 159 76 298 498
2025/20262.498 352 582 893 671 0 0 0 0 0 0 0 0
Totale 10.108